JP2023503050A5 - - Google Patents

Info

Publication number
JP2023503050A5
JP2023503050A5 JP2022529015A JP2022529015A JP2023503050A5 JP 2023503050 A5 JP2023503050 A5 JP 2023503050A5 JP 2022529015 A JP2022529015 A JP 2022529015A JP 2022529015 A JP2022529015 A JP 2022529015A JP 2023503050 A5 JP2023503050 A5 JP 2023503050A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
cancer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/061288 external-priority patent/WO2021102143A1/en
Publication of JP2023503050A publication Critical patent/JP2023503050A/ja
Publication of JP2023503050A5 publication Critical patent/JP2023503050A5/ja
Pending legal-status Critical Current

Links

JP2022529015A 2019-11-19 2020-11-19 免疫モジュレーター Pending JP2023503050A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962937517P 2019-11-19 2019-11-19
US62/937,517 2019-11-19
US202062957355P 2020-01-06 2020-01-06
US202062957361P 2020-01-06 2020-01-06
US62/957,361 2020-01-06
US62/957,355 2020-01-06
PCT/US2020/061288 WO2021102143A1 (en) 2019-11-19 2020-11-19 Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases

Publications (2)

Publication Number Publication Date
JP2023503050A JP2023503050A (ja) 2023-01-26
JP2023503050A5 true JP2023503050A5 (https=) 2023-10-02

Family

ID=73835801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529015A Pending JP2023503050A (ja) 2019-11-19 2020-11-19 免疫モジュレーター

Country Status (7)

Country Link
US (1) US20230022400A1 (https=)
EP (1) EP4061818B1 (https=)
JP (1) JP2023503050A (https=)
KR (1) KR20220100950A (https=)
CN (1) CN114641480A (https=)
ES (1) ES2970395T3 (https=)
WO (1) WO2021102143A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087857B1 (en) 2020-01-06 2023-11-01 Bristol-Myers Squibb Company Immunomodulators
KR20220161407A (ko) * 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2021226460A1 (en) * 2020-05-08 2021-11-11 Bristol-Myers Squibb Company Immunomodulators
JP2024526072A (ja) * 2021-06-09 2024-07-17 ブリストル－マイヤーズ スクイブ カンパニー 環状ペプチド免疫調節剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2016039749A1 (en) * 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9809625B2 (en) * 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) * 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators

Similar Documents

Publication Publication Date Title
JP2023503050A5 (https=)
JP2023510737A5 (https=)
JP2023510736A5 (https=)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
JP2021063120A5 (https=)
JP2016503414A5 (https=)
JP2013539795A5 (https=)
JP2012525329A5 (https=)
CA2736177A1 (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
JP2020525429A5 (https=)
JP2023500834A5 (https=)
JP2020532529A5 (https=)
JP2017533266A5 (https=)
JP2011509949A5 (https=)
JP2018508572A5 (https=)
TR201809990T4 (en) NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING.
JP2013522292A5 (https=)
JP2020532539A5 (https=)
JP2016519062A5 (https=)
JP2012153722A5 (https=)
RU2014125230A (ru) Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность
JP2010538091A5 (https=)
JP2020532537A5 (https=)
JP2013199483A5 (https=)